Companies
/Healthcare
Biogen Inc
$253.40
▲ $2.92 (+1.17%) today
Markets closed · 12:57pm ET
Biogen (BIIB) Earnings History & Trends
86%
EPS beat rate
+30.55%
Avg. EPS surprise
Consecutive EPS beats
BIIB vs Market · 30-day return after each reportBIIBS&P 500
BIIB EPS Trend · estimate vs actualEstimateActual
BIIB Revenue Trend · estimate vs actualEstimateActual
How Often Does Biogen Beat Earnings Estimates?
Biogen beat EPS estimates in 6 of its last 7 reported quarters, and has beaten 6 quarters in a row.
| Quarter | EPS · est. | Surprise | Revenue · est. | Surprise |
|---|---|---|---|---|
| Q3 2026 Non-GAAP EPS of $2.62 includes $284 million of acquired IPR&D, upfront and milestone expense, primarily related to the acquisition of RayThera Inc. GAAP EPS of $(0.14) further includes $194.8 million amortization of inventory fair value step-up, $172.8 million amortization of acquired intangible assets, $82.1 million restructuring charges, $33.3 million loss on equity security investments, and $26.6 million litigation matters. | $2.62 est. $1.97 | +32.74% | $2.8B est. $2.6B | +6.54% |
| Q2 2026 | $3.60 est. $2.07 | +73.61% | $2.7B est. $2.5B | +11.37% |
| Q1 2026 | $3.57 est. $2.95 | +20.93% | $2.5B est. $2.2B | +10.22% |
| Q4 2025 | $1.99 est. $1.63 | +22.09% | $2.3B est. $2.2B | +3.42% |
| Q3 2025 | $4.81 est. $3.88 | +23.88% | $2.5B est. $2.3B | +8.20% |
| Q2 2025 | $5.47 est. $3.87 | +41.31% | $2.6B est. $2.3B | +13.90% |
| Q1 2025 | $3.02 est. $3.04 | −0.72% | $2.4B est. $2.2B | +8.80% |
Figures from SEC filings and company reports. Not investment advice.